Biogen Points to Enrollment and Dosing to Explain Alzheimer’s Results

The potentially multi-billion dollar question that underpinned the presentation was why, of the two studies Biogen (NADSAQ: BIIB) conducted of aducanamab, did one meet the primary endpoint of reducing clinical decline while the other failed—and what that dichotomy reveals about the drug’s efficacy and its chances for approval.